Every hour 30 people are diagnosed with tuberculosis in the European Region. It’s time to make TB a disease of the past
The latest ECDC-WHO report Tuberculosis surveillance and monitoring in Europe 2019 (2017 data) shows that despite an overall decline in numbers of people suffering from TB, the disease remains a major public health challenge in the Region. Of the 275 000 new diagnoses and relapses, an estimated 77 000 people are suffering from difficult-to-treat multidrug-resistant TB (MDR-TB). The European Union and European Economic Area (EU/EEA) countries fare better, with only 1 041 people reported to have MDR-TB. However, most countries in the Region, including many in the EU/EEA, struggle to treat patients successfully.
Dr Vytenis Andriukaitis, European Commissioner for Health and Food Safety, said: "Even though tuberculosis is an ancient, preventable and curable disease, it still causes too much suffering and death to many people in the European Union and beyond. TB was high on the global agenda in 2018 and world leaders committed to mobilise efforts towards ending it. This momentum must be used to tackle tuberculosis from all angles and at all levels. The Commission has pledged its commitment to support the EU Member States towards reaching the goal of ending TB by 2030 as part of the wider Sustainable Development Agenda. Even though we are on the right track, sustained efforts centred on people are paramount to achieve a tuberculosis-free Europe and the world."
ECDC Director Dr Andrea Ammon believes in the capacity of the EU/EEA to improve:
We can end TB by 2030. However, as the burden in the region varies greatly, we will need to tailor approaches on a country-by-country basis. ECDC will continue to offer tailored country support and coordinate efforts across borders.
“TB is preventable and curable; the time to take action is now to end TB by 2030. If we don’t act rapidly and decisively, the drug-resistant forms of the disease will increase their hold on Europe. Despite the challenges and threats that we face, I believe that Europe has the full potential to lead the way. We have science and technology, skilled health professionals and high level political commitment to leaving no-one behind - we have got what it takes to end TB.” said Dr Zsuzsanna Jakab, WHO Regional Director for Europe.
The recent United Nations High-Level Meeting on TB, held in September 2018, brought hope to the world as global leaders stepped up their commitment to end TB by 2030, in line with the Sustainable Development Goals (SDGs). This political commitment now needs to be translated into action to end TB.
New hope for treatment of drug-resistant TB
Up until now, an MDR-TB diagnosis spelled the start of a gruelling two-year treatment plan for patients. New WHO recommendations for the treatment of MDR-TB involve safer and more effective drugs with reduced chances of severe side effects and a new treatment regimen for increased effectiveness.
This is also a welcome change for the EU/EEA countries struggling to successfully treat drug-resistant patients. In 2017, only 45% of patients with MDR-TB were treated successfully and for extensively drug-resistant TB (XDR-TB), the more resistant form of the disease, only 28% were reported as successfully treated.
Timely diagnostic tests are vital
Proper and fast diagnosis of TB is essential. The sooner a patient is diagnosed, the faster their treatment can begin, easing suffering and preventing further disease transmission. The new report indicates that just over half of all newly notified TB patients were tested using WHO-recommended rapid diagnostic tests. To improve diagnoses and ensure appropriate treatment approaches, it is also important to have capacity at country level to rapidly detect drug-resistant TB.
Overall, the situation in the European Region is improving too slowly to end TB by 2030. In order to reach the SDG target on TB, new intersectoral approaches are required, current tools need to be used more effectively and a people-centred approach to care is paramount.
Read the report
Tuberculosis surveillance and monitoring in Europe, 2019
This report provides an overview of the latest TB epidemiological situation and is published jointly by the WHO Regional Office for Europe and the European Centre for Disease Prevention and Control (ECDC).
Notes to the editor
World Tuberculosis Day is observed on 24 March each year around the world. Its overall goal is to raise awareness concerning the burden of TB worldwide and the status of TB prevention and control efforts.
Sustainable Development Goal target 3.3: “By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases”. The indicator is TB incidence per 100 000 population. The WHO End TB Strategy sub-targets for measuring progress towards the SDGs are: TB incidence 80% lower in 2030 compared to 2015; the number of TB deaths 90% lower; and no family should face catastrophic costs due to TB.
The United Nations High-level Meeting on TB was held on 26 September 2018, resulting in a political declaration endorsed by heads of state and government outlining the key commitments that must be met for the world to end the TB epidemic by 2030, as called for in the SDGs.
The WHO European Region comprises 53 countries with a population of over 900 million, of which around 517 million live in the EU/EEA (28 EU Member States plus Iceland, Liechtenstein and Norway).
In the 31 EU/EEA countries, 55 337 TB cases were reported in 2017, with a notification rate of 10.7 per 100 000 population. MDR-TB was reported for 1 041 (3.8%) of the 27 339 cases with the relevant drugsusceptibility test (DST) results and XDR-TB was reported for 187 (24.3%) of 770 MDR-TB cases with the relevant DST results.
World Tuberculosis Day - 2019
24 Mar 2019 to 24 Mar 2019 - World Tuberculosis Day, marked each year on 24 March, is an occasion to raise awareness and advocate for efforts to eliminate TB. It is high time to end TB.
Tuberculosis (TB) is a serious infectious disease that can be fatal. It most commonly affects the lungs.Read more